Netanya S Utay1,2, Ana N Monczor3, Anoma Somasunderam1, Sofia Lupo3, Zhi-Dong Jiang4, Ashley S Alexander2, Malcolm Finkelman5, Karen J Vigil3, Jordan E Lake3, Blake Hanson4, Herbert L DuPont2,4, Roberto C Arduino3. 1. Division of General Medicine, Department of Internal Medicine, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas. 2. Kelsey Research Foundation, Houston, Texas. 3. Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas. 4. School of Public Health at The University of Texas Health Science Center at Houston, Houston, Texas. 5. Associates of Cape Cod Inc., Falmouth, Massachusetts.
Abstract
BACKGROUND: Reduced microbiota diversity (dysbiosis) in people with HIV (PWH) likely contributes to inflammation, a driver of morbidity and mortality. We aimed to evaluate the safety and tolerability of 6 weekly oral fecal microbiota transplants (FMT) administered to reverse this dysbiosis. METHODS: Six PWH on suppressive antiretroviral therapy (ART) received 6 weekly doses of lyophilized fecal microbiota product from healthy donors. Shotgun sequencing on stool before, after last FMT, and 20 weeks thereafter was performed. Inflammation and gut permeability biomarkers were measured. RESULTS: Median age at week 0 was 39 years, CD4+ T cell count 496 cells/mm3, HIV RNA levels <20 copies/mL. FMT was safe and well-tolerated. α diversity increased in 4 participants from weeks 0 to 6, including the 3 with the lowest α diversity at week 0. At week 26, α diversity more closely resembled week 0 than week 6 in these 4 participants. Metagenomic analysis showed no consistent changes across all participants. One participant had high gut permeability and inflammation biomarker levels and low α diversity that improved between weeks 0 and 6 with a shift in distribution. CONCLUSIONS: Weekly FMT was safe and well-tolerated. α diversity increased in participants with the lowest baseline α diversity during the treatment period. Future randomized, controlled trials of FMT should consider evaluating PWH with greater inflammation, gut damage, or dysbiosis as this population may be most likely to show a significant response.ClinicalTrials.gov Identifier: NCT03329560.
BACKGROUND: Reduced microbiota diversity (dysbiosis) in people with HIV (PWH) likely contributes to inflammation, a driver of morbidity and mortality. We aimed to evaluate the safety and tolerability of 6 weekly oral fecal microbiota transplants (FMT) administered to reverse this dysbiosis. METHODS: Six PWH on suppressive antiretroviral therapy (ART) received 6 weekly doses of lyophilized fecal microbiota product from healthy donors. Shotgun sequencing on stool before, after last FMT, and 20 weeks thereafter was performed. Inflammation and gut permeability biomarkers were measured. RESULTS: Median age at week 0 was 39 years, CD4+ T cell count 496 cells/mm3, HIV RNA levels <20 copies/mL. FMT was safe and well-tolerated. α diversity increased in 4 participants from weeks 0 to 6, including the 3 with the lowest α diversity at week 0. At week 26, α diversity more closely resembled week 0 than week 6 in these 4 participants. Metagenomic analysis showed no consistent changes across all participants. One participant had high gut permeability and inflammation biomarker levels and low α diversity that improved between weeks 0 and 6 with a shift in distribution. CONCLUSIONS: Weekly FMT was safe and well-tolerated. α diversity increased in participants with the lowest baseline α diversity during the treatment period. Future randomized, controlled trials of FMT should consider evaluating PWH with greater inflammation, gut damage, or dysbiosis as this population may be most likely to show a significant response.ClinicalTrials.gov Identifier: NCT03329560.
Authors: R I Glass; J Noel; T Ando; R Fankhauser; G Belliot; A Mounts; U D Parashar; J S Bresee; S S Monroe Journal: J Infect Dis Date: 2000-05 Impact factor: 5.226
Authors: Robert P Hirten; Ari Grinspan; Shih-Chen Fu; Yuying Luo; Mayte Suarez-Farinas; John Rowland; Eduardo J Contijoch; Ilaria Mogno; Nancy Yang; Tramy Luong; Philippe R Labrias; Inga Peter; Judy H Cho; Bruce E Sands; Jean Frederic Colombel; Jeremiah J Faith; Jose C Clemente Journal: Inflamm Bowel Dis Date: 2019-05-04 Impact factor: 5.325
Authors: Tricia H Burdo; Margaret R Lentz; Patrick Autissier; Anitha Krishnan; Elkan Halpern; Scott Letendre; Eric S Rosenberg; Ronald J Ellis; Kenneth C Williams Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Stephan J Ott; Georg H Waetzig; Ateequr Rehman; Jacqueline Moltzau-Anderson; Richa Bharti; Juris A Grasis; Liam Cassidy; Andreas Tholey; Helmut Fickenscher; Dirk Seegert; Philip Rosenstiel; Stefan Schreiber Journal: Gastroenterology Date: 2016-11-17 Impact factor: 22.682
Authors: Duraisamy Ponnusamy; Elena V Kozlova; Jian Sha; Tatiana E Erova; Sasha R Azar; Eric C Fitts; Michelle L Kirtley; Bethany L Tiner; Jourdan A Andersson; Christopher J Grim; Richard P Isom; Nur A Hasan; Rita R Colwell; Ashok K Chopra Journal: Proc Natl Acad Sci U S A Date: 2016-01-05 Impact factor: 11.205
Authors: Zhi-Dong Jiang; Robert R Jenq; Nadim J Ajami; Joseph F Petrosino; Ashley A Alexander; Shi Ke; Tehseen Iqbal; Andrew W DuPont; Kenneth Muldrew; Yushu Shi; Christine Peterson; Kim-Anh Do; Herbert L DuPont Journal: PLoS One Date: 2018-11-02 Impact factor: 3.240
Authors: Christopher Staley; Thomas Kaiser; Byron P Vaughn; Carolyn T Graiziger; Matthew J Hamilton; Tauseef Ur Rehman; Kevin Song; Alexander Khoruts; Michael J Sadowsky Journal: Microbiome Date: 2018-09-18 Impact factor: 14.650